Contract Research Organisation hVIVO plc (AIM: HVO), a company that specialises in human challenge clinical trials, on Wednesday announced positive results from a Phase 2a trial conducted for Shionogi & Co Ltd. The study evaluated the investigational oral RSV antiviral candidate S-337395, which holds Fast Track designation from the US FDA.
The randomised, placebo-controlled, double-blind trial, conducted using healthy volunteers recruited through FluCamp, demonstrated an 88.94% reduction in viral load at the highest dose (P
Novartis' Fabhalta (iptacopan) receives US FDA approval
WuXi Biologics honoured for water security by CDP
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Niagen Bioscience secures US patent for nicotinamide riboside salt forms
Sobi forms research collaboration for development of Gamifant in sepsis
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
Health Canada approves KEYTRUDA for advanced or recurrent endometrial carcinoma
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
SIFI enters scientific collaboration with UCSF on Acanthamoeba Keratitis
Johnson & Johnson's nipocalimab granted FTD for treatment of Sjogren's disease
Vascarta launches phase I VAS101 clinical study in osteoarthritis
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
Evommune enrols first patient in EVO301 Phase 2 trial
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab